ArticleAntimicrobial agents and chemotherapy2011
Saturability of granulocyte kill of Pseudomonas aeruginosa in a murine model of pneumonia.
Article in Antimicrobial agents and chemotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review.Clinical pharmacokinetics · 2019Pooled it
- Modeling Phage-Antibiotic Synergy, Innate Immunity, and Phage Resistance in Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Evaluation of Short Versus Long Course of Tobramycin Combined with Piperacillin/Tazobactam Against Antibiotic-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Towards modeling phage therapy.PLoS computational biology · 2026Article
- Pharmacokinetic-pharmacodynamic modeling to evaluate the relative impact of immune response and meropenem on bacterial killingAntimicrobial agents and chemotherapy · 2026Article
- Model-based quantification of immune response and anti-staphylococcal activity of afabicin in immunocompetent mouse thigh infections to enable predictions of clinical efficacy.Antimicrobial agents and chemotherapy · 2026Article
- Glucocorticoid-mediated suppression of the CCL2-CCR2 axis drives monocyte dysfunction in severe pneumonia among immunocompromised hosts.Respiratory research · 2025Article
- Comparative In Vitro Killing of Key Bovine Respiratory Bacterial Pathogens by Pradofloxacin and Eight Other Veterinary Antimicrobial Agents.Microorganisms · 2025Article
- Cancer microbiota: a focus on tumor-resident bacteria.EMBO reports · 2025Review
- Quantifying phage-bacteria dynamicsmicroPublication biology · 2025Article
- Metapopulation model of phage therapy of an acutemSystems · 2024Article
- Metapopulation model of phage therapy of an acutebioRxiv : the preprint server for biology · 2024Article
- Battle royale: Immune response on biofilms - host-pathogen interactions.Current research in immunology · 2023Review
- Predicting Antimicrobial Activity at the Target Site: Pharmacokinetic/Pharmacodynamic Indices versus Time-Kill Approaches.Antibiotics (Basel, Switzerland) · 2021Review
- PK/PD Analysis by Nonlinear Mixed-Effects Modeling of a Marbofloxacin Dose Regimen for Treatment of Goat Mastitis Produced by Coagulase-Negative Staphylococci.Animals : an open access journal from MDPI · 2021Article
- Effects of Growth Medium and Inoculum Size on Pharmacodynamics Activity of Marbofloxacin againstAntibiotics (Basel, Switzerland) · 2021Article
- Combating Multidrug-Resistant Bacteria by Integrating a Novel Target Site Penetration and Receptor Binding Assay Platform Into Translational Modeling.Clinical pharmacology and therapeutics · 2021Article
- Development of New Tuberculosis Drugs: Translation to Regimen Composition for Drug-Sensitive and Multidrug-Resistant Tuberculosis.Annual review of pharmacology and toxicology · 2021Review
- Mechanistic Modeling of Mycobacterium tuberculosis Infection in Murine Models for Drug and Vaccine Efficacy Studies.Antimicrobial agents and chemotherapy · 2020Article
- Quantitative Models of Phage-Antibiotic Combination Therapy.mSystems · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Outcomes for patients with dense bacterial burdens, such as ventilator-associated pneumonia (VAP) patients, are often critically influenced by the adequacy of antimicrobial chemotherapy and by the response of the immune system, particularly the granulocytes. Little information is available about the quantitation of kill of organisms over time by granulocytes. In this investigation, we examined the impact of the baseline bacterial burden on the ability of granulocytes alone (without chemotherapy) to keep the number of organisms in check or to kill them over a 24-h period. Pseudomonas aeruginosa ATCC 27853 was the study organism, and we employed a murine pneumonia model (granulocyte replete) for the study. We found that the ability of the immune system to kill P. aeruginosa was saturable. The burden at which the system was half saturated was 2.15 × 10⁶ ± 2.66 × 10⁶ CFU/g. Burdens greater than 10⁷ CFU/g demonstrated net growth over 24 h. These findings suggest the need for aggressive chemotherapy early in the treatment of VAP to keep the burden from saturating the granulocytes. This should optimize the outcome for these seriously infected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.